RSS Rigel Pharma: FDA Grants Orphan Drug Designation To R289 - Quick Facts

Currently reading:
 RSS Rigel Pharma: FDA Grants Orphan Drug Designation To R289 - Quick Facts

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
10,950
Likes
1,923
Credits
33,627©
Cash
0$
Rigel Pharmaceuticals (RIGL) has announced that the FDA has awarded Orphan Drug status to R289 for the treatment of myelodysplastic syndromes. Prior to this, R289 had also received Fast Track designation for addressing the needs of patients with previously-treated, transfusion-dependent, lower-risk myelodysplastic syndromes.

Rigel's CEO, Raul Rodriguez, stated, "The Orphan Drug and Fast Track designations, combined with promising initial data from our ongoing Phase 1b study in patients with lower-risk MDS, mark essential milestones in progressing R289 as a potential new treatment option."

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom